Its bone-loss treatment denosumab, which could bring in $2 billion to $3 billion a year, is closer to FDA approval. But not all experts are sold on it
BusinessWeek.com --, Business Week
Tue, 08/11/2009 - 7:00am
Its bone-loss treatment denosumab, which could bring in $2 billion to $3 billion a year, is closer to FDA approval. But not all experts are sold on it